Latest News - Biogen
Top Corporates Hub
Biogen
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
08.09.2026 14:30
FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available. The September 10 summit at The Harvard Club of Boston will bring together CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology leaders to discuss AI governance, Agen
Lilly Builds Neuroscience into a New Long-Term Growth Driver
08.09.2026 12:27
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
04.09.2026 04:38
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
03.09.2026 11:06
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
03.09.2026 04:00
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (Chinese trademark: 乐意保®
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
03.09.2026 03:25
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
03.09.2026 03:25
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
01.09.2026 12:30
BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The g
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
01.09.2026 07:31
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
01.09.2026 00:30
An Important Step Forward for Access to LEQEMBI® for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of LEQEMBI® (lecanemab) for eligible patients in Canada living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD). The final recommendation follows a r
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
26.08.2026 08:02
TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
26.08.2026 08:02
TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
13.08.2026 13:52
Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
Biogen (BIIB) Q2 2026 Earnings Call Transcript
08.08.2026 00:02
Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
01.08.2026 15:47
Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.
Biogen Q2 Earnings Call Highlights
29.07.2026 14:04
Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth port
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
29.07.2026 14:00
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher
29.07.2026 12:16
Biogen (NASDAQ:BIIB) reported stronger-than-expected second-quarter results on Wednesday, with revenue and adjusted earnings exceeding Wall Street forecasts as its expanding portfolio of growth products continued to offset weakness in its legacy multiple sclerosis business. The biotechnology company posted revenue of $2.
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
29.07.2026 12:15
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.
Why This Drugmaker’s Earnings Guidance Cut Doesn’t Tell the Full Story
29.07.2026 12:02
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.